首页> 外文期刊>Annals of vascular surgery >Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.
【24h】

Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.

机译:台湾在批准静脉内组织纤溶酶原激活剂治疗前后,使用尿激酶进行局部动脉内溶栓治疗以治疗急性缺血性中风。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Local intra-arterial thrombolysis (LIT) has been previously suggested as an effective therapy for acute ischemic stroke. In this study, we describe our experience of using LIT for the treatment of Taiwanese patients with ischemic stroke at different vascular locations, before and after Alteplase was approved as a first-line treatment in Taiwan. The criteria required for the initiation of LIT have become more stringent after the approval of Alteplase (AA). METHODS: A retrospective analysis of medical records was conducted for 20 ischemic stroke patients treated with LIT; including 10 patients treated before and 10 patients treated after AA (we did not treat any of the patients in this study with AA). Urokinase was used for LIT treatment. Outcome measures included patient demographics, clinical characteristics, and clinical outcomes before and after LIT. Clinical outcomes were evaluated using four different stroke scales. RESULTS: The median National Institutes of Health stroke scale score (NIHSS) before treatment was reported to be 19.2 (range: 8-30). After AA, only one patient who had an occluded internal carotid artery (ICA) was treated with LIT. Among the 20 patients, 11 (55%) (five before AA and six after AA) reported having favorable or good clinical outcomes within 3 months of treatment, whereas five reported having poor outcomes (three before AA and two after AA), and the rest four patients died following treatment (two before AA and two after AA). Arterial recanalization was reported as complete in 10 patients (50%; seven middle cerebral artery [MCA] and three basilar artery; six before AA and four after AA), as incomplete in four patients (20%; one MCA and three basilar artery; one before AA and three after AA), and it failed in the remaining six patients (30%; two MCA and four ICA; three before AA and three after AA). Five patients (one MCA and four ICA) in whom recanalization had failed reported having poor outcomes, including one ICA patient who subsequently succumbed to the illness. Intracranial hemorrhagic and intraventricular hemorrhage transformation occurred in three and two patients, respectively. A case of intraventricular hemorrhage transformation after AA was also reported. CONCLUSION: On the basis of our experience, we found that LIT was of limited value in patients with ICA occlusion before AA approval. After AA, the outcomes in acute stroke patients, who were receiving urokinase therapy and who were carefully selected on the basis of the site of occlusion, were improved.
机译:背景:局部动脉内溶栓(LIT)先前已被建议作为急性缺血性中风的有效疗法。在这项研究中,我们描述了在Alteplase被批准为台湾一线治疗前后,使用LIT治疗台湾地区不同血管位置的缺血性中风患者的经验。 Alteplase(AA)批准后,启动LIT所需的标准变得更加严格。方法:对20例接受LIT治疗的缺血性中风患者进行病历回顾性分析。包括10位在AA之前接受治疗的患者和10位在AA之后接受治疗的患者(我们未在本研究中使用AA治疗任何患者)。尿激酶用于LIT治疗。结果指标包括LIT前后的患者人口统计学,临床特征和临床结局。临床结果使用四种不同的卒中量表进行评估。结果:据报道,治疗前美国国立卫生研究院中风量表评分(NIHSS)为19.2(范围:8-30)。 AA后,只有一名颈动脉内动脉闭塞(ICA)的患者接受LIT治疗。在20例患者中,有11例(55%)(AA前5例,AA后6例)在治疗后3个月内报告了良好或良好的临床结果,而5例患者预后较差(AA前3例,AA后2例),其余4例患者在治疗后死亡(AA前2例,AA后2例)。据报道,10例患者(50%; 7条大脑中动脉[MCA]和3条基底动脉; AA之前6条,AA后4条)的动脉再通已完成,4例患者(20%; 1条MCA和3条基底动脉; 6条AA)未完成。一名在机管局之前,三名在机管局之后),其余六名患者失败(30%;两名MCA和四名ICA;三名在机管局前,三名在机管局后)。再通失败的五名患者(一名MCA和四名ICA)报告预后不良,包括一名后来死于该病的ICA患者。颅内出血和脑室内出血转化分别发生在三名和两名患者中。也有报道AA后发生脑室内出血的病例。结论:根据我们的经验,我们发现在AA批准之前,ICA闭塞患者的LIT价值有限。 AA后,接受尿激酶治疗并根据闭塞部位精心选择的急性中风患者的预后得到改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号